Irbesartan Aurovitas

Irbesartan, the active ingredient in Irbesartan Aurovitas, is an angiotensin II receptor blocker presented as an oral tablet for oral use. It is employed to manage high blood pressure and to protect kidney function in patients with diabetic nephropathy. GNH USA supplies Irbesartan Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan belongs to the ARB class and is used to treat conditions related to the renin‑angiotensin system.

Hypertension: lowers elevated blood pressure and reduces cardiovascular risk. Diabetic nephropathy: slows progression of kidney damage in patients with type 2 diabetes.

Irbesartan may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue or weakness - Nausea or abdominal discomfort - Upper respiratory tract infection - Mild increase in serum potassium

Serious or Rare Side Effects: - Angioedema involving face, lips, tongue or throat - Severe hypotension, especially in volume‑depleted patients - Acute kidney injury or worsening renal function - Hyperkalemia with potentially life‑threatening cardiac effects - Hepatic injury presenting as jaundice or elevated liver enzymes

Before initiating therapy, several safety considerations should be observed. - Blood pressure monitoring: check regularly to avoid excessive hypotension. - Renal function: assess serum creatinine and eGFR before and during treatment. - Serum potassium: monitor for hyperkalemia, especially with potassium‑sparing agents. - Hepatic impairment: use caution and adjust dose if liver disease is present. - Pregnancy: avoid use; potential fetal toxicity is not established. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Concomitant use with aliskiren in diabetic patients: increased risk of renal impairment and hyperkalemia. - Dual blockade with ACE inhibitors or other ARBs: heightened risk of hypotension, renal dysfunction, and hyperkalemia. - Potassium‑sparing diuretics (e.g., spironolactone): may cause dangerous elevations in serum potassium.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can reduce antihypertensive effect and impair renal function. - Lithium: may increase lithium levels, leading to toxicity. - Diuretics (thiazides or loop): may enhance antihypertensive effect and affect electrolyte balance.